Transaction with Sosei Heptares "Sosei Deal" On July 20, 2023, Idorsia sold its operating businesses in the Asia Pacific (ex-China) region to Sosei Heptares for a total consideration of CHF 400 million. The territories within the scope of the transaction are Australia, Brunei, Cambodia, Indonesia, Japan, Laos, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Thailand, Taiwan, and Vietnam, hereafter the "Territories". The Sosei Deal includes the sale of Idorsia's Japanese and South Korean affiliates, the assignment of the license for PIVLAZ (clazosentan) for the Territories, the co-exclusive license for daridorexant for the Territories and the assignment of all potential milestones in connection with the co-exclusive license of daridorexant granted to Mochida Pharmaceutical.